Capricorn Partners is an independent manager of venture capital, growth capital and quoted equity funds, focusing on innovative companies that use technology as a competitive advantage.

Capricorn Partners

Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as a competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is managing the venture capital funds Capricorn Sustainable Chemistry Fund, Capricorn Digital Growth Fund, Capricorn ICT Arkiv, Capricorn Health‐tech Fund, Capricorn Cleantech Fund, Capricorn Fusion China Fund and Capricorn Industrial Biotech Fund. In addition, it is the management company of Quest for Growth, quoted on Euronext Brussels, and the investment manager of Quest Cleantech Fund and Quest+, sub‐funds of Quest Management SICAV, registered in Luxembourg.

🔬 Innovating at nanoscale while creating a macroscale impact!

 Our portfolio company, VOID Technologies, is doing just that by using nanoscale air pockets to reduce plastic usage and enhance recyclability in plastic film manufacturing. 🌍♻️

 📰 Check out this month’s edition of Plastics Technology, which highlights how VOID is enabling brand owners and film converters to create a new generation of voided films and packaging solutions, helping to achieve critical plastic reduction and recycling goals.

James Gibson Rob van der Meij Ludwig Goris Yvette Go Wouter Van de Putte Daniela Arruda Costa Damien van der Bijl

🚀 Capricorn Partners leads €4M Series A round for Thryve, a pioneering B2B health data integration and analytics company together with IBB Ventures, CRB Health Tech SGEIC and CARMA FUND Management GmbH.

💊 This investment aligns perfectly with our strategy on personalized prevention and therapeutic solutions. Already serving over 50 million people across Europe, Thryve’s platform empowers insurers and digital therapeutics providers to deliver proactive, personalized care, driving better health outcomes and reducing costs.

Looking forward to working together with Friedrich Lämmel, Paul Burggraf and John T..

👉 Read more: https://lnkd.in/et4n7VpM

Katrin Geyskens Marc Lambrechts Antoine D'Hollander Simon Wouters Steven Lambert Filip Pintelon Ine Jordens

🏅 Watching the Olympics is thrilling, with the world's best athletes pushing human limits in a spectacular display of skill and determination.

⚙️ But behind the scenes, no sports thrive without composites and chemicals! Even more, the sports industry is an innovative lab for lightweight, sturdy, and sustainable materials.

Though not yet in the Olympics, our startups are champions in driving sustainability with eco-friendly molecules and materials:

🚴 REIN4CED is revolutionizing the bicycle industry with a new composite material that blends carbon's lightness with steel's toughness.

🌿 Trillium Renewable Chemicals introduces sustainable acrylonitrile, essential for producing carbon fiber used in bicycles, tennis rackets, hockey sticks, and sailing gear.

👟 Econic Technologies Ltd transforms CO2 into polyurethane foams, adding cushion and support to your sporting shoes.

Enjoy the Olympics! 🏅


Rob van der Meij  Ludwig Goris  Daniela Arruda Costa  Yvette Go  Wouter Van de Putte  Damien van der Bijl

🚀Our Belgian portfolio company icometrix is on the verge of a major breakthrough in the US thanks to reimbursement code. 

Icometrix, a leader in AI-based brain scan analysis which already analyzed 200k brain scans, is achieving significant milestones in the United States. The decision by American insurers to reimburse its technology marks a major advancement for this Belgian company, founded by Wim Van Hecke. This move has tripled the value of contracts, reflecting the growing demand for Icometrix’s innovative solutions.

We're a proud investor in Icometrix since 2015, when AI and digital health were emerging fields. Even then, we recognized the potential 🌍 impact of this innovative Belgian company 

Thanks for this great article De Tijd.

Dirk Smeets Katrin Geyskens Marc Lambrechts Jos. B. Peeters

🌍 August 1st marks #EarthOvershootDay 2024, the day when we've used up all the resources the planet can generate this year. 

🌿 Our startups are driving sustainable innovations in chemistry, biotech, and energy, enhancing resource and energy efficiency. Together, we aim to #MoveTheDate of Earth Overshoot Day.

DMC Biotechnologies, Inc. Zeopore Technologies NV VOID Technologies Econic Technologies Ltd Qpinch NEFFA | New Fashion Factory Gradyent

🍾  €60M Series B round for our portfolio company Confo Therapeutics 

This round is led by Ackermans & van Haaren together with Driehaus Capital Management LLC and our Quest for Growth

The proceeds will be used to advance their pipeline of novel GPCR-Modulating Therapies into clinical development. This significant milestone will support  two Phase 1 trials and advance two additional programs to IND approval.

🔬 Their R&D efforts will expand, focusing on discovering new development candidates for rare endocrine diseases and obesity.

As Capricorn Partners, we've proudly supported Confo Therapeutics since 2015.  Jos. B. Peeters, Chairman of the Board of Capricorn Partners, states, "We’ve been co-founders of this company and have been supporting it since then. We are delighted with the progress of the company and are looking forward to its promising future."

Looking forward to the next years and congratulations to Cedric Ververken and the complete Confo team!

👉 Read more: https://lnkd.in/e5SMZQ46

Filip Pintelon Sabine Vermassen Katrin Geyskens

🌞 Perfect to listen while walking in the sun today! 🌞

Our partner, Rob van der Meij, has been invited to join Victoria (King) Meyer on The Chemical Show Podcast! 🎙️ They delve into the fascinating world of sustainable investing, leadership in company growth, and the unique challenges faced by startups in the chemical and clean tech industries. 🌱⚙️

Listen via spotify: https://lnkd.in/ez7JJ2SR

Hope you enjoy it!

🚀Our portfolio company FEops joins forces with Materialise 🚀

Materialise has just acquired our portfolio company FEops, a pioneering Belgian company in AI-driven simulation technology for structural heart interventions! This acquisition marks a significant milestone in advancing personalized treatment for heart diseases. 

“At Materialise, we are pioneering the advent of mass-personalization in healthcare, using advanced visualization and 3D printing technologies to deliver precise, patient-specific solutions," said Brigitte de Vet-Veithen de Vet, CEO of Materialise.

We have been a proud investor in FEops since 2015 and have enjoyed working together with Matthieu De Beule, Peter Mortier and Isabelle Decroos to scale this company to a global commercial company together with PMV and Valiance.

Wishing the best to everyone as FEops joins the Materialise family, uniting two strong Belgian companies! 🌟

Read more: https://lnkd.in/eYQaxV-M

Marc Lambrechts Katrin Geyskens Antoine D'Hollander Jos. B. Peeters

🌟 Continuing our journey into responsible investing at Capricorn Partners, today we highlight how our Capricorn cleantech activities align with several United Nations Sustainable Development Goals (SDGs).
 
🔍 The Capricorn Sustainable Chemistry Fund & Capricorn Industrial Biotech fund supports companies that contribute to:
 
• SDG 9: Industry, Innovation, and Infrastructure.
 
• SDG 12: Responsible Consumption and Production
 
🌱 While these are our targeted SDGs, our portfolio companies often align with other SDGs as well.
 
💡 Stay tuned for upcoming posts, where we'll explore the potential impact of our portfolio companies' technologies!

Wouter Van de Putte Yvette Go Rob van der Meij Daniela Arruda Costa Ludwig Goris Damien van der Bijl

🌐 ExCulture: The second investment for our Capricorn Dutch Industrial Biotech Seed Fund 🚀
  
ExCulture, based on technology developed at Delft University of Technology, is developing a novel and sustainable method to produce essential biomedical compounds through fermentation. The first target is Heparin, which is the world’s most used blood thinner and currently still produced as a by-product of pig slaughter. ExCulture’s platform enables animal-free, reliable and sustainable production of Heparin.
 
The Dutch Industrial Biotech Seed Fund is a part of the Capricorn Industrial Biotech Fund and is an initiative of Capricorn Partners, dsm-firmenich and InnovationQuarter to provide crucial early-stage funding and expert guidance for ventures with industrial biotechnology applications at their core. The fund is managed by the Cleantech Team of Capricorn Partners and has been awarded additional RVO Seed Capital / Seed Business Angel Regeling  funding by the Dutch government.

We are proud to work with Innovation Industries as co-investors in this round. The investment complements earlier funding and support from Delft Enterprises B.V. UNIIQ, Libertatis Ergo Holding B.V.  and Planet B.io and will allow the company to progress its platform on the way to regulatory approval.

👉 Read more: https://lnkd.in/eNt9vj9k
 
We are looking forward to our collaborative journey with ExCulture are committed to supporting the company's sustainable innovation. 🌿

Damien van der Bijl Daniela Arruda Costa Rob van der Meij pieter wolters Jareth van der Putten Pleuni Hooijman, PhD Margherita Marchetti, PhD Céline van der Heijden

Metric
Company Name	Capricorn Partners
Symbol
MSH ID	BE:CAPRICORN
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Management
Country	BE
Stage
Employee Count
Website	capricorn.be
LinkedIn	capricornpartners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CAPR

BE:CAPRICORN

Capricorn Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue